[Neurofeedback therapy in the treatment of tinnitus].

Neurofeedback therapy is a fast-growing field of tinnitus treatment, which is a new type of biofeedback therapy. In the past, the "muscle tone" and "blood flow" were used as feedback signals in biofeedback therapy to treat tinnitus, however there was no long-term follow-up report. Instead, neurofeedback therapy utilizes EEG (electroencephalogram) as the feedback signal, which is also called EEG biofeedback therapy. At present, most treatments of tinnitus only record subjective measures of patients as evaluation indicators, whereas neurofeedback therapy is more convincing for using comprehensive evaluation including changes of brain wave as objective indicators and subjective measures of patients. A significant number of tinnitus patients have varying degree of hearing loss. As neurofeedback therapy takes advantage of EEG as feedback signal that is delivered to the patients through visual information, it has unique advantages of being not affected by the degree of hearing loss compared to the sound masking or other sound treatment. Long-term follow-up results showed that the efficacy of neurofeedback therapy was stable after half a year of short-term treatment. This paper summarizes the progress of the various types of biofeedback therapy in the treatment of tinnitus, and focuses on the neurofeedback therapy for the mechanism, indication, process, efficacy evaluation, defect and prospect of neurofeedback therapy in tinnitus treatment in order to help promote the development of domestic clinical neurofeedback therapy in tinnitus.

Clinical application of remifentanil in local anesthesia for tumor resection in functional brain area.

OBJECTIVE: The aim of this study was to investigate clinical application of remifentanil in local anesthesia for resection of tumors in functional brain area. PATIENTS AND METHODS: Twenty-four patients were randomly divided into two groups: control group and remifentanil group. In remifentanil group remifentanil was infused intravenously with micro pump in 0.05-0.1 µg·kg-1·min-1. The hemodynamic changes and complications during operation were monitored. RESULTS: The satisfactory degree for surgical procedure was evaluated. The surgery of two groups could be completed in a conscious state. Mean artery pressure (MAP), heart rate (HR) in remifentanil group during opening or closing skull or intra- cranial period were significantly lower than control group (p < 0.05). There were no conspicuous complications in two groups such as respiratory depression, nausea, vomitting and dysphoria. Satisfaction rate of remifentanyl group was significantly higher than control group (p < 0.05). CONCLUSIONS: Awake brain tumor surgery could be completed in rational use of remifentanil on the base of good local anesthesia, and hemodynamics were stable and the patients were well tolerated.

[Biotransformation of (+)- and (-)-clausenamide in rats].

AIM: To study the metabolic pathway of chiral clausenamide in the rat and understand its stereoselectivity. METHODS: The urine, feces and blood of rat were gathered after the drug was administered, the known metabolites were analyzed by HPLC-DAD and one unknown metabolite was elucidated by using LC-MS analysis. Metabolic stereoselectivity was determined by comparing the metabolic results of (+)- and (-)-clausenamide. RESULTS: Six known metabolites were determined and one unknown metabolite was elucidated as N-demethylclausenamide. The metabolic stereoselectivity was shown distinctly. CONCLUSION: Chiral clausenamide was mainly metabolized by hydroxylation in liver and the biotransformation exhibited pronounced substrate stereoselectivity.